During the past decade, Arizona Retina and Vitreous Consultants conducted 20 clinical trials. In the 10-year time frame, 20 clinical trials started and 9 clinical trials were completed, i.e. on average, 45% percent of trials that started reached the finish line to date. In the past 5 years, 9 clinical trials started and 9 clinical trials were completed. i.e. 100% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Arizona Retina and Vitreous Consultants" #1 sponsor was "Hoffmann-La Roche" with 9 trials, followed by "Jaeb Center for Health Research" with 3 trials sponsored, "Aerpio Therapeutics" with 1 trials sponsored, "Allergan" with 1 trials sponsored and "Apellis Pharmaceuticals, Inc." with 1 trials sponsored. Other sponsors include 1 different institutions and companies that sponsored additional 11 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Arizona Retina and Vitreous Consultants" #1 collaborator was "National Eye Institute (NEI)" with 2 trials as a collaborator, "National Institutes of Health (NIH)" with 2 trials as a collaborator, "Regeneron Pharmaceuticals" with 2 trials as a collaborator, "Juvenile Diabetes Research Foundation" with 1 trials as a collaborator and "Kowa Company, Ltd." with 1 trials as a collaborator. Other collaborators include -4 different institutions and companies that were collaborators in the rest 6 trials.

According to Clinical.Site data, the most researched conditions in "Arizona Retina and Vitreous Consultants" are "Diabetic Macular Edema" (7 trials), "Diabetic Retinopathy" (3 trials), "Geographic Atrophy" (3 trials), "Macular Degeneration" (3 trials) and "Neovascular Age-Related Macular Degeneration" (2 trials). Many other conditions were trialed in "Arizona Retina and Vitreous Consultants" in a lesser frequency.

Most popular intervention types in "Arizona Retina and Vitreous Consultants" are "Drug" (19 trials), "Other" (5 trials), "Procedure" (4 trials), "Biological" (1 trials) and "Combination Product" (1 trials). Other intervention types were less common.

The name of intervention was led by "Sham Procedure" (7 trials), "Faricimab" (5 trials), "Placebo" (4 trials), "Ranibizumab" (3 trials) and "Aflibercept" (2 trials). Other intervention names were less common.

The vast majority of trials in "Arizona Retina and Vitreous Consultants" are 21 trials for "All" genders.

Currently, there are NaN active trials in "Arizona Retina and Vitreous Consultants". undefined are not yet recruiting, 1 are recruiting, 6 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 10 completed trials in Arizona Retina and Vitreous Consultants, undefined suspended trials, and 4 terminated clinical trials to date.

Out of the total trials that were conducted in Arizona Retina and Vitreous Consultants, 0 "Phase 1" clinical trials were conducted, 6 "Phase 2" clinical trials and 15 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".